Literature DB >> 28229568

Yo-Yo IR1 vs. incremental continuous running test for prediction of 3000-m performance.

Boris Schmitz1, Andreas Klose2, Katrin Schelleckes3, Charlotte M Jekat4, Michael Krüger2, Stefan-Martin Brand4.   

Abstract

BACKGROUND: This study aimed to compare physiological responses during the Yo-Yo intermittent recovery level 1 (Yo-Yo IR1) Test and an incremental continuous running field Test (ICRT) and to analyze their predictive value on 3000-m running performance.
METHODS: Forty moderately trained individuals (18 females) performed the ICRT and Yo-Yo IR1 Test to exhaustion. The ICRT was performed as graded running test with an increase of 2.0 km·h-1 after each 3 min interval for lactate diagnostic. In both tests, blood lactate levels were determined after the test and at 2 and 5 min of recovery. Heart rate (HR) was recorded to monitor differences in HR slopes and HR recovery.
RESULTS: Comparison revealed a correlation between ICRT and Yo-Yo IR1 Test performance (R2=0.83, P<0.001), while significant differences in HRmax existed (Yo-Yo IR1, 189±10 bpm; ICRT, 195±16 bpm; P<0.005; ES=0.5). Maximum lactate levels were also different between test (Yo-Yo IR1, 10.1±2.1 mmol∙L-1; ICRT, 11.7±2.4 mmol∙L-1; P<0.01; ES=0.7). Significant inverse correlations were found between the Yo-Yo IR1 Test performance and 3000 m running time (R2=0.77, P<0.0001) as well as the ICRT and 3000 m time (R2=0.90, P<0.0001).
CONCLUSIONS: Our data suggest that ICRT and Yo-Yo IR1 test are useful field test methods for the prediction of competitive running performances such as 3000-m runs but maximum HR and blood lactate values differ significantly. The ICRT may have higher predictive power for middle- to long- distance running performance such as 3000-m runs offering a reliable test for coaches in the recruitment of athletes or supervision of training concepts.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28229568     DOI: 10.23736/S0022-4707.17.07097-9

Source DB:  PubMed          Journal:  J Sports Med Phys Fitness        ISSN: 0022-4707            Impact factor:   1.637


  6 in total

1.  Dose-Response of High-Intensity Training (HIT) on Atheroprotective miRNA-126 Levels.

Authors:  Boris Schmitz; Katrin Schelleckes; Johanna Nedele; Lothar Thorwesten; Andreas Klose; Malte Lenders; Michael Krüger; Eva Brand; Stefan-Martin Brand
Journal:  Front Physiol       Date:  2017-05-30       Impact factor: 4.566

2.  The Yo-Yo Intermittent Tests: A Systematic Review and Structured Compendium of Test Results.

Authors:  Boris Schmitz; Carina Pfeifer; Kiana Kreitz; Matthias Borowski; Andreas Faldum; Stefan-Martin Brand
Journal:  Front Physiol       Date:  2018-07-05       Impact factor: 4.566

3.  Retina Vascular Perfusion Dynamics During Exercise With and Without Face Masks in Healthy Young Adults: An OCT Angiography Study.

Authors:  Dihao Hua; Yishuang Xu; Peter Heiduschka; Wenliang Zhang; Xiao Zhang; Xiangbing Zeng; Xiangxiang Zhu; Tao He; Hongmei Zheng; Xuan Xiao; Yiqiao Xing; Zhen Chen; Changzheng Chen
Journal:  Transl Vis Sci Technol       Date:  2021-03-01       Impact factor: 3.283

4.  Longer Work/Rest Intervals During High-Intensity Interval Training (HIIT) Lead to Elevated Levels of miR-222 and miR-29c.

Authors:  Boris Schmitz; Florian Rolfes; Katrin Schelleckes; Mirja Mewes; Lothar Thorwesten; Michael Krüger; Andreas Klose; Stefan-Martin Brand
Journal:  Front Physiol       Date:  2018-04-17       Impact factor: 4.566

5.  Correlation analysis of physical fitness and retinal microvasculature by OCT angiography in healthy adults.

Authors:  Pieter Nelis; Boris Schmitz; Andreas Klose; Florian Rolfes; Maged Alnawaiseh; Michael Krüger; Nicole Eter; Stefan-Martin Brand; Florian Alten
Journal:  PLoS One       Date:  2019-12-03       Impact factor: 3.240

6.  Sex Differences in High-Intensity Interval Training-Are HIIT Protocols Interchangeable Between Females and Males?

Authors:  Boris Schmitz; Hannah Niehues; Lothar Thorwesten; Andreas Klose; Michael Krüger; Stefan-Martin Brand
Journal:  Front Physiol       Date:  2020-01-29       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.